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ABSTRACT 
Background and objectives: Atherosclerosis is highly prevalent in chronic kidney disease 
(CKD). The rate of progression of atherosclerosis is associated with cardiovascular events. 
Fibroblast growth factor 2 (FGF-2) is a member of the FGF family with potentially both 
protective and deleterious effects in the development of atherosclerosis. The role of 
circulating FGF-2 levels in the progression of atherosclerosis in CKD is unknown.  
Design, setting, participants, & measurements: Multicenter, prospective observational 
study in 481 CKD patients form the NEFRONA cohort. We determined the presence of 
atheroma plaque in 10 arterial territories by carotid and femoral ultrasounds. Progression 
of atheromatosis was defined as an increase in the number of territories with plaque after 
24 months. Plasma levels of FGF-2 were measured by multiplex analysis. A multivariable 
logistic regression analysis was performed to determine whether plasma FGF-2 levels 
were associated with atheromatosis progression. 
 Results Average age of the population was 61 years. The percentage of patients in each 
CKD stage was 51% in stage 3, 41% in stage 4-5 and 8% in dialysis. 335 patients (70%) 
showed plaque at baseline. Atheromatosis progressed in 289 patients (67%).  FGF-2 levels 
were similar between patients with or without plaque at baseline (79 vs 88 pg/ml), but 
lower in patients with atheromatosis progression after 2 years (78 vs 98 pg/ml. p<0.01). In 
adjusted analyses, higher plasma FGF-2 was associated with lower risk of atheromatosis 
progression (OR 0.86 (95% CI 0.76-0.96) per 50 pg/mL increment). Analysis of FGF-2 in 
tertiles showed that atheroma progression was observed for 102 participants in the 
lowest tertile of FGF-2 (reference group), 86 participants in the middle tertile of FGF-2 
(adjusted OR 0.70, 95% CI 0.40-1.20) and 74 participants in the lowest tertile of FGF-2 
(adjusted OR 0.48, 95% CI 0.28-0.82). 
Conclusions: Low FGF-2 levels are independently associated with atheromatosis 
progression in CKD.  
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INTRODUCTION 
 
 
Chronic kidney disease (CKD) is a growing public health problem worldwide and, 
over the past decade, it has developed into an area of intensive clinical and 
epidemiological research. Patients with CKD, even at early stages, demonstrate higher risk 
for the development of cardiovascular disease (CVD), 1, 2 enhancing morbidity and 
mortality in this population.3 A variety of traditional cardiovascular risk factors such as 
hypertension, diabetes, dyslipidemia2 and non-traditional variables such as endothelial 
cell dysfunction, 4 inflammation, 2 low vitamin D levels 5, 6 or hyperphosphatemia 7-9 begin 
to act very early in the course of CKD, accelerating the pathogenesis of cardiovascular 
disease. Taking into account that traditional and CKD-specific risk prediction equations 
explain only a portion of the cardiovascular disease associated with CKD, the search for 
new risk factors for cardiovascular disease in CKD patients continues. 
Atherosclerotic cardiovascular disease is highly prevalent in CKD patients 7 and its 
progression is closely associated with the progression of CKD.10 The role of atherosclerosis 
in the increased cardiovascular mortality in CKD patients seems clear, although its 
contribution in late stages is controversial. Indeed, there are differences in the type of 
cardiovascular events and the associated factors along the progression of CKD. Thus, in 
early stages, there is a high mortality rate due to ischemic events, related to 
atherosclerosis.11 However, in dialysis patients most of the deaths seem to be caused by 
heart failure and sudden cardiac death, although subclinical atherosclerosis appears to be 
influencing the higher susceptibility of the myocardium of those patients to electrolyte 
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imbalances.12 Indeed, atheroma burden also independently predicts cardiovascular events 
in dialysis, and the rate of atherosclerotic plaque formation predicts cardiovascular events 
in those patients.13 Therefore, the determination of factors that affect atherosclerosis 
progression in CKD could lead to therapeutic targets specific for CKD patients.   
Fibroblast growth factor 2 (FGF-2 or bFGF) is a member of a large family of 
heparin-binding proteins14 that has an important role in the pathogenesis of 
atherosclerosis, but it also has cardioprotective actions. FGF-2 affects essential biological 
activities of vascular cells such as differentiation, proliferation and migration, showing a 
dual role in the cardiovascular system. The expression of FGF-2 and its receptors in a 
normal vessel wall is highly beneficial for the maintenance of the vascular homeostasis 
and protection of endothelial cells. 15 However, FGF-2 and its receptors play a role in the 
inflammatory process, intimal thickening and intra-plaque angiogenesis,16 stimulating 
proliferation and migration of vascular smooth muscle cells (VSMC) 14, 17 and development 
of vasa vasorum in atherosclerotic lesions,18 therefore accelerating atherosclerotic plaque 
growth.  
There are scarce clinical data investigating the role of circulating levels of FGF-2 in 
atherosclerosis. Only few studies have demonstrated that levels of FGF-2 did not correlate 
with carotid obstruction grade19 or coronary artery calcification in the general 
population.4 However, to date, no investigation has been conducted analyzing the role of 
circulating FGF-2 levels in atheromatosis progression. In the present work, we analyzed 
the association between FGF-2 and progression of atheromatosis burden in a 
subpopulation of the the NEFRONA study. 
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METHODS 
Design & study population 
The protocol of the study was approved by the ethics committee of each hospital 
and all patients were included after signing informed consent. This research followed the 
principles of the Declaration of Helsinki. The design and objectives of the NEFRONA study 
have been already published in detail.20, 21 Briefly, 2445 CKD patients (937 in CKD stage 3, 
820 in stage 4-5 and 688 in dialysis) without a history of previous cardiovascular disease 
who were 18-75 years of age were enrolled from 81 Spanish hospitals between October 
2009 and June 2011, with a scheduled follow-up visit after 24 months. Patients from the 
NEFRONA study who had hemodynamically significant stenotic carotid plaque, ankle-
brachial index (ABI) <0.7 at baseline, a cardiovascular event or received a renal allograft 
along the 2 year’s follow up, or died after the first ultrasound exploration were excluded 
from the follow-up. Thus, 1555 were followed for 24 months. Out of those, 481 had 
available plasma samples to measure FGF-2 levels. Samples from the other patients had 
already been spent to measure other biomarkers in sub-studies within the NEFRONA 
study.22, 23 In any case, both populations did not differ in most of the parameters of the 
study, although there was a lower proportion of patients in dialysis than in the total 
sample. Consequently, high sensitivity C-reactive protein (hsPCR) levels were lower and 
25(OH)D, total and LDL cholesterol levels were higher in the analyzed sample 
(Supplemental table S1). 
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Determination of FGF-2 in plasma samples 
FGF-2 levels were measured in duplicate in frozen plasma samples after the end of the 
recruitment period. The detection was performed with multiplex kits (Milliplex MAP, 
Merck Millipore), an assay specially designed to identify 10 different biomarkers in a small 
sample by an Elisa-like method. The assay uses internally color-coded microspheres 
coated with specific primary antibodies. After a molecule from a test sample is captured 
by the bead, an additional biotinylated antibody, built to identify another epitope of the 
molecule, is introduced. Thus, the emission of the bead identifies the compound and the 
intensity if the second antibody quantifies the amount of the compound. The multiplex 
panel included FGF2, Eotaxin, GM-CSF, Fractalkine, IFN-gamma, MDC, IP-10, MCP-1, MIP-
1Beta and VEGF. The purpose of the study was to identify whether those analytes, which 
have been previously associated to cardiovascular disease, were associated with 
atherosclerosis progression in CKD. Out of those, only FGF2 showed an association with 
the outcome, after Bonferroni´s correction for multiple testing. 
In order to determine whether the method of recollection of the samples was interfering 
with the results, we measured in the multiplex kit 40 samples of in-house patients frozen 
immediately after extraction and compared the results against the same samples stored at 
4ºC for 24 hours (in order to mimic the conditions of the samples during the shipment 
from the extraction place to the biobank in which they were stored). The Pearson’s 
correlation coefficient was 0.99 (p<0.001) showing that the handling of the samples 
before storage did not affect the levels of FGF2. The inter-assay coefficient of variability of 
this analyte is 4.8%. 
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Clinical data and Laboratory examinations 
Current health status, medical history, baseline cardiovascular risk factors and drug 
use information was obtained at baseline. A physical examination was performed, 
consisting of anthropometric measures, standard vital tests and ABI measurements as 
previously described.24 A pathological ABI was described as ≤ 0.9 or ≥ 1.4. Biochemical 
data were obtained from a routine fasting blood test within three months from the 
vascular study.  Previous and current smokers were classified as ever smokers. Diagnosis 
of dyslipidemia was obtained from the clinical history. Glomerular filtration rate (GFR) was 
estimated using the Modification of Diet in Renal Disease Study formula (MDRD-4).   
Ultrasound Imaging 
B-mode ultrasound of the carotid and femoral arteries was performed using the 
Vivid apparatus (General Electric) equipped with a 6-13 MHz broadband linear array probe 
as previously described. 25 Briefly, ultrasound imaging was performed with the subjects in 
a supine position and the head turned 45º contralateral to the side of the probe to 
evaluate carotid plaques.  The presence of atheromatous plaques was defined as a IMT > 
1.5 mm protruding into the lumen, according to the ASE Consensus Statement26 and the 
Mannheim IMT Consensus.27  
The presence of atheromatous plaques was explored in 10 territories (both 
internal, bulb and common carotids, and both common and superficial femoral arteries) 
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by a single reader in blinded mode, using semi-automatic software (EchoPAC Dimension, 
General Electric Healthcare). Therefore, a score from 0 to 10 was assigned to every patient 
both at basal and at the follow up exploration two years later; 0 meaning no plaques in 
any territorie and 10 the presence of atheroma plaque in all 10 territories explored. To 
assess intraobserver reliability, a sample of 20 individuals was measured 3–5 times on 
different days by a reader unaware of patients’ clinical history. An intraclass correlation 
coefficient of 0.8 was obtained for plaque assessment, indicating very good intraobserver 
reliability. Intima-media thickness (IMT) was only measured in arterial regions without 
plaque and calculated as the average between left and right sides. When a territory 
presented with a plaque, IMT value was censored to be 1.5 mm in that territory. The 
average of the IMT value of the 10 territories was calculated and presented as the 
patient’s IMT.  
Evaluation of Progression  
Atheromatosis progression was defined as an increase in the number of territories 
showing a plaque with respect to the baseline visit, as previously used in the MESA 
study.28  The analysis was performed in 10 arterial territories, yielding a score of 1 to 10 
both, at the baseline (SB) and at the follow up (SFU) visit. The outcome variable 
(atheromatosis progression) was defined as an increase in the number of territories with 
plaque with respect to the basal visit. Thus, if SFU - SB > 0 the patient was assigned to the 
group of progressors. If SFU - SB = 0 the patient was assigned to the group of non-
progressors. In no patient a negative value of (SFU - SB) was observed.   
9 
 
Statistical analysis 
Univariable relationship between the levels of the ten compounds measured in the 
multiplex analysis with plaque presence and progression at 24 months was analyzed by 
Student’s t test for normally distributed variables, and Mann-Whitney’s test in non-
parametric analysis. In order to account for the multiple testing problem, Bonferroni’s 
correction was applied. Thus, only p values equal or lower than 0.005 were considered 
statistically significant in the univariate analysis. Significant variables in univariable 
analyses and potential confounders were used to develop appropriate multivariable 
logistic regression models. A forward step procedure was used to build the multivariable 
model, including the variable showing maximum contribution identifying those patients 
with 24-month atheromatosis progression, according to the likelihood ratio test (LRT). 
Those variables without a statistically significant contribution, but modifying in more than 
10% the value of the coefficients of any of the significant variables when removed from 
the model, were considered confounders and included in the final model. Possible first 
degree interactions between FGF-2 and different parameters were tested. A statistical 
significance level of 0.05 was used. A sensitivity analysis using FGF-2 as a categorical 
variable was also built. All analyses were made using a standard statistical package (SPSS 
24.0). 
RESULTS 
The characteristics of the population, grouped by tertiles of FGF-2, are shown in 
Table 1. The median age was 61 years, and the median (p25-p75) plasma FGF-2 levels 
were 85 (55-138)pg/mL. Table 2 shows the univariable analysis of factors associated with 
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atheromatosis progression. Of the 289 patients that progressed, 157 (54%) did so in one 
territory, 75 (26%) in two, 36 (13%) in three, 14 (5%) in four, 4 (1%) in five, 2 (0.7%) in six 
and 1 (0.3%) seven new territories were affected after 24 months.  The univariable 
analysis (table 2) showed that patients in whom atherosclerosis progressed were 
significantly older, more frequently smokers and with a higher percentage of patients with 
diabetis and hypertension and had higher blood levels of triglycerides, glucose and hsCRP. 
Furthermore, the IMT values and the percentage of patients with plaque at baseline was 
also higher in progressors.  
As seen in Figures 1A and B, FGF-2 levels did not differ among patients with or 
without plaque at baseline neither between patients with different atheromatosis burden. 
However, Figure 1C shows that FGF-2 levels were significantly lower in patients in which 
atherosclerosis progressed after 2 years of follow-up, compared with patients where the 
plaque burden remained stable. In addition, FGF-2 levels were significantly lower in 
patients with more advanced CKD stages (Figure 2). 
The unadjusted analysis modeling atherosclerosis progression (Table 3, model 1) 
shows that higher levels of FGF-2, assessed as a continuous variable, are associated with 
lower progression of atherosclerosis. Adjustment for age and sex (model 2) and by several 
known risk factors for atheromatosis progression (model 3) show that the effect of FGF-2 
remains unmodified. A sensitivity analysis using FGF-2 as a categorical variable (tertiles) 
yielded similar results.  The possible interactions between FGF-2 levels and several 
parameters (including CKD stage) were tested and disregarded as nonsignificant.  The 
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Hosmer and Lemeshow p values show an excellent goodness of fit of the logistic 
regression model, so the model is considered well calibrated. 
 
DISCUSSION 
 
The present work shows that FGF-2 levels are associated with atherosclerosis 
progression in CKD patients. This effect is independent of other parameters known to 
affect the progression of atherosclerosis in CKD like age, the degree of renal function, the 
levels of cholesterol or the smoking status. Therefore, FGF-2 could be considered as a 
marker and potential target in atherosclerosis progression in CKD patients.  
The role of FGF-2 in atherosclerosis is unclear, and preclinical data show that 
beneficial and detrimental effects could coexist. On the one hand, FGF-2 may be 
deleterious due to its potential to increase plaque size. Thus, FGF-2 and FGF receptors are 
expressed in VSMC29 and FGF-2 induces VSMC proliferation in vitro. 17 Furthermore, FGF-2 
promotes VSMC migration by inducing matrix metalloproteases (MMP) 2 and 9 expression 
in baboon aortic explants30 and by regulating TRAIL expression in mice undergoing the cuff 
injury model.31 In addition, FGF-2 could regulate VSMC phenotypic transformation from 
the contractile to the synthetic phenotype, a necessary step in the early stages of 
atherosclerosis.32 Thus FGF-2 has been shown to act synergistically with platelet-derived 
growth factor inducing the phenotypic change in vitro.33 In any case, and although FGF-1 
levels increase in atherosclerotic plaques versus normal artery tissue, FGF-2 levels have 
been reported to remain normal in human atherosclerotic artery samples.29 
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On the other hand, the effects of FGF-2 in endothelial cells point to a beneficial 
effect on atherosclerosis. Atherosclerotic disease is a progressive disorder that develops 
over a long period of time, triggered locally by endothelial dysfunction. FGF-2 increases 
proliferation and migration of endothelial cells34 and, furthermore, maintains their 
integrity,15, 35 antagonizing endothelial dysfunction. In addition, administration of FGF-2 
improves endothelial function decreasing vascular endothelial adhesion molecule 
expression and macrophage infiltration early on in the course of experimental 
atherosclerosis.36 
In vivo studies in experimental models of atherosclerosis have yielded 
controversial results. Thus, Che et al. showed that endothelial overexpression of FGF 
receptor 2 accelerates atherosclerosis in a transgenic mouse model.37 Raj et al. also 
showed that pharmacological inhibition of FGF receptor signaling with a tyrosine kinase 
activity inhibitor attenuated atherosclerosis in apolipoprotein E null mice.38 However, the 
effects observed in the former studies could be attributed to signaling of any of the 23 FGF 
species described so far. In experiments using specifically FGF-2, direct administration of 
the compound did not increase neointimal formation after balloon injury in pigs,39 dogs,40 
rabbits41  and it even decreased neointimal formation in a rat model of balloon injury 42 
and in a rabbit model of poor distal runoff circulation. 43 In any case, the potential 
different effects of FGF-2 on experimental atherosclerosis could be explained by the 
different effect of the compound depending on the stage of evolution of plaque, from 
type I plaques with relatively normal histology and endothelial dysfunction, to 
complicated type VI plaques with thrombus. Thus, in early stages, increased FGF-2 levels 
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can prevent the formation of plaque by reducing endothelial dysfunction.36 By contrast, in 
aadvanced lesions where endothelial dysfunction is no longer an issue, FGF-2 pro-
mitogenic actions can induce plaque growth and even rupture by increasing the density of 
vasa-vasorum and MMP synthesis.44, 45 In our study, lower FGF-2 levels are associated with 
the appearance of new plaques, but were not associated with the baseline presence of 
atheroma plaques, agreeing with a protective role of FGF-2 in the early stages of 
atheroma plaque formation. Indeed, clinical trials using FGF-2 as a treatment for 
revascularization have not shown any effect aggravating atherosclerotic disease.46, 47 
Our results disclosing a higher odds ratio (OR) for atheromatosis progression in 
CKD stages 4-5 and dialysis than in stage 3 patients may appear discordant with those of 
Rigatto et al48 observing lower progression of atheromatosis in later CKD stages. In our 
study, the OR for atheromatosis progression was higher in stages 4-5 and dialysis 
compared with stage 3 patients. However, the design of both studies differ, and those 
differences may account for the discrepancies. First, our cohort specifically excluded CKD 
patients with previous cardiovascular disease, while one third of patients in Rigatto’s 
cohort, had a previous cardiovascular event. Furthermore, our study explored the femoral 
territories, which were not tested in Rigatto´s study. Finally, a possible interaction 
between FGF-2 levels and CKD stage could also explain the discrepancy, although that 
interaction was tested and disregarded as non-significant.  
Another result from our study shows that FGF-2 levels are lower in more severe CKD 
stages, reaching very low levels in dialysis patients. There is little information about the 
role of FGF-2 in CKD. Experimental data show that FGF-2 could be a therapeutic tool to 
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reduce CKD. FGF-2 administration reduces functional and structural damage in 
experimental CKD.49 Furthermore, FGF-2 mediates the improvement of renal function 
induced by the administration of mesenchymal stem cells in a rat model of CKD.50 Thus, 
FGF-2 could have a potential role in the progression of CKD, although further research is 
warranted. 
The main strength of this study is the relatively large number of patients with 
longitudinal observations, which allows us to make associations controlling for multiple 
confounders. A second strength is that the vascular exploration was performed by the 
same team and evaluated by a single reader. Nevertheless, our study also has some 
limitations. The main one is that, out of the total sample of the patients followed for 
atherosclerosis progression, only a portion had available plasma sample to measure FGF-2 
levels. Therefore, the subpopulation might not be representative of the full cohort, as 
some parameters differed between patients with available sample and the rest. However, 
the number of patients is still high enough to adjust for many potential confounding 
factors. Furthermore, patients that died or suffered a cardiovascular event were also 
unavailable for the follow up visit, alongside patients that underwent a kidney transplant. 
Therefore, we can not exclude survival bias, since individuals with poor CV health were 
excluded. Another limitation of the study is the fact that the detection method is a 
multiplex assay, and results should be validated with a method specific for the FGF-2. 
Furthermore, the observational nature of the study and the unclear biologic function of 
the measured circulating FGF-2 are additional limitations. 
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In summary, lower FGF-2 levels are associated with atheromatosis progression in 
CKD patients. Further research is needed to determine whether FGF-2 could be a 
therapeutic target to reduce atheromatosis progression in renal patients. 
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Table 1. Baseline characteristics of 481 participants in the NEFRONA cohort study according to plasma fibroblast growth factor-2 
concentration . 
 
 All (n=481) Lower tertile  
(3-64 pg/mL) 
(n=160) 
Middle tertile 
(65-119 pg/mL) 
(n=160) 
Higher tertile  
(120-865 pg/mL) 
(n= 161) 
Age, years 61 (52-68) 61 (53-68) 61 (50-68) 61 (50-68) 
Male, N (%) 295 (61) 107 (67) 94 (59) 94 (58) 
History of Smoking, N (%) 283 (59) 91 (61) 88 (55) 98 (61) 
Dyslipidemia, N (%) 336 (70) 107 (67) 114 (71) 115 (71) 
Diabetes Mellitus, N (%) 137 (29) 43 (27) 51 (32) 43 (27) 
Hypertension, N (%) 442 (92) 150 (94) 147 (92) 145 (90) 
SBP, mmHg 142 (20) 142 (20) 142 (20) 141 (20) 
DBP, mmHg 81 (10) 81 (11) 81 (10) 81 (11) 
Total Cholesterol, mg/dL 180 (156-207) 179 (148-206) 184 (165-209) 180 (157-206) 
LDL-cholesterol, mg/dL 104 (85-126) 102 (75-124) 106 (93-128) 104 (87-128) 
HDL-cholesterol, mg/dL 47 (38-59) 47 (39-58) 47 (37-61) 47 (39-61) 
Triglycerides, mg/dL 127 (90-171) 133 (89-171) 133 (91-180) 117 (88-164) 
Glucose, mg/dL 98 (88-114) 99 (87-111) 99 (90-129) 95 (89-112) 
25-hydroxyvitamin D, ng/mL 16.7 (11.9-21.4) 16.1 (12.0-21.0) 17.5 (12.2-21.9) 15.7 (11.1-21.2) 
IMT, mm 0.86 (0.67-1.1) 0.86 (0.71-1.14) 0.86 (0.65-1.1) 0.84 (0.64-1.1) 
Hs-CRP, mg/L 2.12 (1.13-4.52) 2.12 (1.04-4.52) 1.97 (1.15-4.36) 2.16 (1.21-4.73) 
CKD stage, N(%)     
CKD3 
CKD4-5 
Dialysis 
243 (51) 
199 (41) 
39 (8) 
58 (36) 
71 (44) 
31 (20) 
89 (56) 
67 (42) 
4 (2) 
96 (60) 
61 (38) 
4 (2) 
Plaque present at baseline, N (%) 335 (70) 115 (72) 106 (66) 114 (71) 
FGF-2 (pg/mL) 85 (55-138) 43 (26-55) 85 (73-100) 164 (138-204) 
Dyslipidemia: Diagnosis of dyslipidemia in the clinical history. SBP: systolic blood pressure; DBP: diastolic blood 
pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; Hs-CRP: high-sensitivity C-reactive protein; 
IMT: average intima/media thickness.  Data are median (p25-p75) for quantitative variables non-normally distributed, 
mean (standard deviation) for normal variables and number (percentage) for categorical variables. 
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the NEFRONA cohort study according to plasma fibroblast growth 
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Table 2. Baseline characteristics of 481 participants in the NEFRONA cohort study according to atherosclerosis progression over the 
subsequent 2 years . 
 
 No (N=192) Yes (N=289) p (no vs. yes) 
Age, years 56 (42-65) 63 (56-69) <0.001 
Male, N (%) 109 (57) 186 (64) 0.10 
Ever smoker, N (%) 100 (52) 183 (63) 0.01 
Dyslipidemia, N (%) 126 (66) 210 (73) 0.11 
Diabetes Mellitus, N (%) 40 (21) 97 (34) 0.002 
Hypertension, N (%) 171 (89) 271 (94) 0.04 
SBP, mmHg 137 (18) 145 (21) <0.001 
DBP, mmHg 80 (10) 81 (11) 0.29 
Total Cholesterol, mg/dL 179 (156-202) 183 (157-213) 0.31 
LDL-cholesterol, mg/dL 102 (85-123) 105 (86-129) 0.39 
HDL-cholesterol, mg/dL 48 (40-61) 47 (37-58) 0.15 
Triglycerides, mg/dL 109 (82-163) 137 (103-176) 0.001 
Glucose, mg/dL 95 (86-105) 102 (91-123) <0.001 
25-hydroxyvitamin D, ng/mL 17.2 (11.8-22.3) 16.2 (11.9-20.7) 0.54 
IMT, mm 0.72 (0.59-1.01) 0.92 (0.75-1.14) <0.001 
Hs-CRP, mg/L 1.87 (1.02-3.77) 2.49 (1.23-5.17) 0.01 
CKD stage, N(%)   0.36 
CKD3 
CKD4-5 
Dialysis 
104 (54) 
72 (38) 
16 (8) 
139 (48) 
127(44) 
23 (8) 
 
Plaque presence at baseline, N (%) 109 (57) 226 (78) <0.001 
Dyslipidemia: Diagnosis of dyslipidemia in the clinical history. SBP: systolic blood pressure; DBP: 
diastolic blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; hs-CRP: high-
sensitivity C-reactive protein; IMT: average intima/media thickness. 
Data are median (p25-p75) for quantitative variables non-normally distributed, mean (standard 
deviation) for normal variables and number (percentage) for categorical variables. 
 
  
Comentado [CJASN21]: Retitle to more clearly describe the 
study population, e.g. “Baseline characteristics of 481 participants in 
the NEFRONA cohort study according to atherosclerosis progression 
over the subsequent 2 years” 
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Table 3: Associations of plasma fibroblast growth factor-2 concentration with atherosclerosis progression in the NEFRONA cohort 
study .Upper row: Model using levels of FGF-2 as a continuous variable. Lower rows: Model using levels of FGF-2 as tertiles 
 Model 1  Model 2 Model 3 
 OR p OR p OR p 
FGF-2 (per 50 pg/ml) 0.86 (0.76-0.96) 0.008 0.85 (0.75-0.95) 0.005 0.86 (0.76-0.96) 0.02 
Hosmer-Lemeshow 0.935 0.759 0.218 
FGF-2 lowest tertile Ref.  Ref.  Ref.  
FGF-2 middle tertile 0.61 (0.37-0.99) 0.05 0.65 (0.39-1.01) 0.11 0.70 (0.40-1.20) 0.20 
FGF-2 highest tertile 0.42 (0.26-0.68) <0.001 0.43 (0.26-0.72) 0.001 0.48 (0.28-0.82) 0.008 
Hosmer-Lemeshow 1.00 0.189 0.691 
Model 1: Unadjusted analysis; Model 2: Adjusted by age and sex; Model 3: model 2 plus smoking status, diabetes, dyslipidemia, plaque 
presence at baseline, stage of chronic kidney disease, intima-media thickness, body mass index, serum levels of glucose, total cholesterol, 
high sensitive C-reactive protein, 25(OH) vitamin D and phosphate. All models included 431 patients (262 progressors and 169 non-
progressors). Lowest tertile of FGF-2 included 143 patients (102 progressors and 41 non-progressors). Middle tertile of FGF-2 included 143 
patients (86 progressors and 47 non-progressors) and highest tertile of FGF-2 included 145 patients (74 progressors and 71 non-
progressors). Ref: Reference tertile. 
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Figure 1: Plasma levels of fibroblast growth factor 2 (FGF-2) in the NEFRONA patients. A) 
Plasma levels in patients with atheromatosis vs. no atheromatosis at baseline. B) Plasma 
levels in patients with no atheromatosis, mild atheromatosis (1 to 3 territories with 
plaque) and severe atheromatosis (more than 3 territories with plaque. C) Plasma levels in 
patients in which atheromatosis progressed after two years vs. those in which remained 
stable. 
 
Figure 2: Plasma levels of fibroblast growth factor 2 (FGF-2) in patients with different 
stages of chronic kidney disease (CKD). 
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